ES2479540T3 - Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades - Google Patents

Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades

Info

Publication number
ES2479540T3
ES2479540T3 ES09748336T ES09748336T ES2479540T3 ES 2479540 T3 ES2479540 T3 ES 2479540T3 ES 09748336 T ES09748336 T ES 09748336T ES 09748336 T ES09748336 T ES 09748336T ES 2479540 T3 ES2479540 T3 ES 2479540T3
Authority
ES
Spain
Prior art keywords
cells
constructs
diseases
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09748336T
Other languages
English (en)
Spanish (es)
Other versions
ES2479540T1 (es
Inventor
Dirk Buescher
La Rosa Olga De
Eleuterio Lombardo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tigenix SA
Original Assignee
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix SA filed Critical Tigenix SA
Publication of ES2479540T1 publication Critical patent/ES2479540T1/es
Application granted granted Critical
Publication of ES2479540T3 publication Critical patent/ES2479540T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09748336T 2008-11-07 2009-11-06 Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades Active ES2479540T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0820397.8A GB0820397D0 (en) 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
GB0820397 2008-11-07
PCT/EP2009/064788 WO2010052313A1 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Publications (2)

Publication Number Publication Date
ES2479540T1 ES2479540T1 (es) 2014-08-20
ES2479540T3 true ES2479540T3 (es) 2016-05-20

Family

ID=40139550

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09748336T Active ES2479540T3 (es) 2008-11-07 2009-11-06 Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades

Country Status (9)

Country Link
US (1) US9012220B2 (enExample)
EP (1) EP2361261B1 (enExample)
JP (1) JP5745419B2 (enExample)
KR (1) KR101666692B1 (enExample)
AU (1) AU2009312700B2 (enExample)
CA (1) CA2742698C (enExample)
ES (1) ES2479540T3 (enExample)
GB (1) GB0820397D0 (enExample)
WO (1) WO2010052313A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
KR20140016933A (ko) * 2011-03-11 2014-02-10 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포군, 분리방법 및 용도들
EP3985105A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population
EP3985106A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395876B1 (en) * 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
EP1252897A4 (en) 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
EP1501918A4 (en) * 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
EP1369114A1 (en) 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
PT1739166E (pt) * 2005-07-01 2011-09-22 Inst Nat Sante Rech Med Obtenção de células tr1 específicas para um auto-antigénio ou antigénio de alimentos a partir de uma população de pbmc ou de leucócito
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
WO2007081878A2 (en) * 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
CA2634072A1 (en) * 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
US20080155704A1 (en) * 2006-12-22 2008-06-26 King's College London Methods and Compositions for Determining in vivo Activity of BiP
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
WO2009155477A1 (en) * 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants

Also Published As

Publication number Publication date
US20120064031A1 (en) 2012-03-15
US9012220B2 (en) 2015-04-21
AU2009312700A1 (en) 2010-05-14
EP2361261A1 (en) 2011-08-31
KR101666692B1 (ko) 2016-10-17
EP2361261B1 (en) 2016-01-27
CA2742698A1 (en) 2010-05-14
CA2742698C (en) 2017-04-18
AU2009312700B2 (en) 2014-06-26
KR20110123721A (ko) 2011-11-15
WO2010052313A1 (en) 2010-05-14
GB0820397D0 (en) 2008-12-17
JP5745419B2 (ja) 2015-07-08
JP2012507997A (ja) 2012-04-05
ES2479540T1 (es) 2014-08-20

Similar Documents

Publication Publication Date Title
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
IL264271A (en) Methods of generating natural killer cells
MX350966B (es) Celulas madre pluripotentes.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MX2012008490A (es) Alteracion genomica dirigida.
SG10201810110RA (en) Extreme pcr
EP2406288A4 (en) VACCINES TREATED ON ANTIGEN PRESENTING CELLS
UY34371A (es) Moléculas de ácido nucleico que se dirigen a rps6 y confieren resistencia a plagas de coleópteros.
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
AR089529A1 (es) Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
WO2012062810A3 (en) Cell culture medium and process for protein expression, said medium and process comprising a pam inhibitor
SG196784A1 (en) Stem cell cultures
CA140016S (en) Battery
CL2011002959A1 (es) Peptoide, metodo para identificar un ligando peptoide que es especificamente reconocido por las celulas autoinmunes; y su uso contre enfermedades autoinmune.
BR112016016524A2 (pt) célula de levedura transformada
WO2012098537A8 (en) Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
CL2013001129A1 (es) Composicion que comprende una celula madre gbm6-ad de glioblastoma purificada; metodo de generacion de anticuerpos especificos para gbm6-ad; dicho anticuerpo; metodo para producir una vacuna de celulas dendriticas; y su uso para el tratamiento de cancer.
MX2011011351A (es) Agentes de imagenologia molecular etiquetados, metodos para hacerlos y metodos de uso.
EA201270577A1 (ru) Усовершенствованные способы обратной генетики для спасения вирусов
WO2012109470A3 (en) Mutant luciferases
WO2011032025A3 (en) Adipose-derived induced pluripotent stem cells
GB2508782A (en) Facile laboratory method for localising biomolecules to the surface of cells and viruses
MX338100B (es) Celulas derivadas de tejido cardiaco.
GB2475627A (en) Resource-availability system and method